Immunomodulation by AZD1656 reverses cardiac dysfunction, metabolic remodelling and reduces infarct size in type 2 diabetic cardiomyopathy.

Anderson S., Karlstaedt A., Chen J., O'Riordan CE., Barnes MR., Štaka Z., Albee LJ., Garrod-Ketchley C., Dambure Vithanachchi ST., Prag HA., Cvetko F., Thiemermann C., Lewis AJ., Murphy MP., Smith DM., Henson SM., Tyler DJ., Aksentijevic D.

DOI

10.1101/2025.04.10.648128

Type

Preprint

Publication Date

2025-04-11T00:00:00+00:00

Keywords

cardio-immunology, inflammation, metabolic remodelling, type 2 diabetes, type 2 diabetic cardiomyopathy

Permalink More information Close